Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: allen menglin chen who wrote (520)	6/28/2000 4:00:00 PM
From: bob zagorin	Respond to of 746

i think you'll see Ventner and CRA mgt. making the rounds, talking about how they take all this firepower and start using it to make money. that will move the stock going forward IMO.

To: allen menglin chen who wrote (520)	6/28/2000 6:00:00 PM
From: Susan G	Read Replies (1) \| Respond to of 746

I think one after another, all the major drug companies and many of the smaller ones will be signing contracts for those 1 million dollar plus subscriptions. How can they not??? And let their competitors get the information first? Sold 1/2 when Clinton started to talk and then bought it all back yesterday. Did you see the money flow on it today? Highest I've seen since last fall.

To: allen menglin chen who wrote (520)	6/28/2000 6:30:00 PM
From: Susan G	Read Replies (1) \| Respond to of 746

Whaddya mean No major news in sight? This is pretty big, and what I expect much more of. Celera Inks 5-Year Genomics Pact With Immunex 06/27/00 ================================================================ ROCKVILLE, MARYLAND, U.S.A., 2000 JUN 27 (NB) -- By Michael P Bruno, Washtech. Celera Genomics Group [NYSE:CRA], already coming off a huge announcement on Monday that it completed the entire mapping and sequencing of one human's genome, said it inked a five-year genomics pact with Seattle-based Immunex Corp. [NASDAQ:IMNX]. The agreement includes a subscription to all four of Celera's genetic code databases. "The database subscription for Immunex gives its researchers access to four databases developed by Celera until 2005," the companies said in a statement. Financial terms were not provided and Celera representatives could not immediately be reached for more information this morning. Reuters reported, though, that several companies that have previously taken five-year subscriptions have each committed to paying Celera $50 million for access. The four databases are: Celera's Human Gene Index, which provides customers with the set of human genes derived from sequencing programs; Celera's Human Genome Database, which is expected to provide the complete sequence of the human genome and the entire collection of human genes with links to associated biological and disease information; The Drosophila Genome Database, which provides the complete sequence of the Drosophila melanogaster genome sequence generated by Celera's whole genome shotgun sequencing strategy, and is annotated with gene, protein and biological information; The Mouse Genome Database being generated by Celera should allow for comparative analysis with the human genome that may be significant for the identification of genes and gene regulatory regions of importance to understanding human biology. All four of Celera's databases include Celera proprietary information as well as publicly available data, Celera said. Access to the databases also provides Immunex with associated comprehensive bioinformatics systems and tools for viewing, browsing, and analyzing genomic information, the company said. Immunex, whose shares are majority owned by U.S. drug maker American Home Products Corp [NYSE:AHP], sells the top-selling arthritis drug Enbrel. Celera, based in Rockville, Md., captured the world spotlight Monday when it announced it had sequenced about 99 percent of the roughly 3.1 billion chemical pairs that make up the human "Book of Life." The publicly funded Human Genome Project concurrently also announced it mapped 97 percent of the genome and sequenced 85 percent of it. Celera shares were off $9.438, or 8.28 percent to $104.562 apiece around 11:30 a.m. EDT today -- which was just above the low reached so far in the trading day. Reported by Washtech.com, washtech.com . (20000627/WIRES PC, BUSINESS/)